StockData
Stryker Corp logo

Stryker Corp (SYK) stock analysis

SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 18/3017% below fair value
$312.39−6.40 (-2.01%)

Close on Nov 12, 2026Market cap $118.92BP/E 33.3Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value3Growth5Performance3Health4Dividend3

Solid18 of 30 checks passed

Stryker passes 18 of the 30 checks behind our score; 6 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
3/6
Growth
5/6
Past performance
3/6
Financial health
4/6
Dividend
3/6

What stands out

  • Trading below fair value

    The share price of $318.79 is below our fair value estimate of $385.07.

  • Earnings grew over 5 years

    Net income grew 15.2% a year on average over the last five fiscal years.

  • Revenue growing 10%+ a year

    Revenue grew 10.8% a year over the last three fiscal years.

  • EPS growing 10%+ a year

    Diluted EPS grew 10.8% a year over the last three fiscal years.

What to watch

  • Margin of safety under 20%

    The price is 17.2% below fair value, less than the 20% cushion we look for.

  • P/E above the industry

    Stryker's P/E of 33.9 is above the Surgical, Medical, and Dental Instruments and Supplies median of 27.7.

  • P/S above the industry

    Stryker's price-to-sales of 4.61 is above the Surgical, Medical, and Dental Instruments and Supplies median of 2.82 (book value is negative, so we use sales).

  • Growing slower than the industry

    Revenue grew 7.9% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 11.0%.

Valuation3/6
  • P/E below its 5-year median

    Stryker's P/E of 33.9 is below its own 5-year median of 42.1.

  • P/E above the industry

    Stryker's P/E of 33.9 is above the Surgical, Medical, and Dental Instruments and Supplies median of 27.7.

  • EV/EBITDA below its 5-year median

    Stryker's EV/EBITDA of 18.9 is below its 5-year median of 35.1.

  • P/S above the industry

    Stryker's price-to-sales of 4.61 is above the Surgical, Medical, and Dental Instruments and Supplies median of 2.82 (book value is negative, so we use sales).

  • Trading below fair value

    The share price of $318.79 is below our fair value estimate of $385.07.

  • Margin of safety under 20%

    The price is 17.2% below fair value, less than the 20% cushion we look for.

Growth5/6
  • Revenue growing 10%+ a year

    Revenue grew 10.8% a year over the last three fiscal years.

  • EPS growing 10%+ a year

    Diluted EPS grew 10.8% a year over the last three fiscal years.

  • Earnings growth accelerating

    Net income grew 23.1% over the last twelve months, against a 5-year average of 15.2% a year.

  • Growing slower than the industry

    Revenue grew 7.9% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 11.0%.

  • Guidance raised

    Stryker raised its full year 2026 adjusted net earnings per diluted share outlook on Jul 30, 2026.

  • Gross margin improving

    Gross margin was 65.3% over the last twelve months, against 64.0% a year earlier.

Past performance3/6
  • Return on equity

    Needs positive equity and five years of results.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity against the industry

    Needs positive equity.

  • Earnings grew over 5 years

    Net income grew 15.2% a year on average over the last five fiscal years.

  • Net margin above its 5-year average

    Net margin was 13.8% over the last twelve months, against a 5-year average of 13.2%.

  • Net margin above the industry

    Stryker's net margin of 13.8% is above the Surgical, Medical, and Dental Instruments and Supplies median of -14.1%.

Financial health4/6
  • Debt level

    Needs debt and equity figures.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 36.5% of total debt.

  • Interest well covered

    Operating income covers interest expense 9.3 times.

  • Short-term assets cover short-term debts

    Current assets are 2.18 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 4.82; above 3 is the safe zone and below 1.8 the distress zone.

Dividend3/6
  • Pays a dividend

    Stryker paid dividends worth 1.1% of the share price over the last twelve months.

  • Yield below Treasuries

    The 1.1% yield is below the 4.4% on a 1-year Treasury.

  • Yield below the top quarter

    The top quarter of US dividend payers yield 3.8% or more; Stryker yields 1.1%.

  • Dividend stability

    Fewer than five years of dividend history.

  • Covered by earnings

    Dividends take 36.8% of net income.

  • Covered by free cash flow

    Dividends take 29.1% of free cash flow.

Scores of similar companies

Our estimate per share

$385.07

The share price is 17% below this estimate.

20%+ below
Near fair value
20%+ above
$318.79Price$385.07Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E35.0×42.1×27.7×$328.2453%
EV/EBITDA26.0×35.1×16.7×$450.0147%
Earnings powerleft out, too far from the others9.0% cost of equity––$106.11–
Fair value$385.07100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 42.1
  • Surgical, Medical, and Dental Instruments and Supplies median 27.7

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$894.44M
Value traded per 1% price move
$517.17M

Downside

Medium risk

Typical loss in a bad month
18.6%
Volatility (annualized)
33%
Sharpe ratio, 1 year
-0.45
Beta to the S&P 500 (5Y)
0.82

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

64.0%+0.9 pts over 5 years

Operating margin

19.5%+4.0 pts over 5 years

Net margin

12.9%+1.8 pts over 5 years

See a number that looks wrong?